Yes, in terms of safety, particularly when the proposed dose for the new indication (MDD) is the same as the approved dose (for Parkinson’s), as it is for this drug.
However, individual MDD trials testing a new agent vs placebo (as an addend to SoC) have a low probability of success compared to trials in most indications, and it’s not uncommon for a sponsor to require four of five phase-3 trials in order to show statsig efficacy in at least two of them.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.